Skip to main content
Clinical Trials/NCT07333859
NCT07333859
Completed
Phase 4

Effect of Intravenous Lidocaine Infusion on Duodenal Peristalsis, Sedation Quality and Rescue Spasmolytic Requirement in ERCP Procedures: A Randomized, Double-Blind, Placebo-Controlled Study

Ankara City Hospital Bilkent1 site in 1 country120 target enrollmentStarted: February 11, 2026Last updated:

Overview

Phase
Phase 4
Status
Completed
Enrollment
120
Locations
1
Primary Endpoint
Rescue Spasmolytic Requirement Rate

Overview

Brief Summary

This study aims to evaluate the efficacy of intravenous lidocaine infusion on duodenal peristalsis during Endoscopic Retrograde Cholangiopancreatography (ERCP). The study compares lidocaine against a placebo to determine if lidocaine can reduce the need for rescue spasmolytics (hyoscine-N-butylbromide or glucagon), decrease propofol consumption, and improve hemodynamic stability.

Detailed Description

Duodenal peristalsis can hinder successful cannulation during ERCP. Traditionally, antispasmodics like hyoscine-N-butylbromide are used but have side effects. This randomized, double-blind, placebo-controlled trial includes 120 patients (ASA I-III) undergoing elective ERCP. "All patients will undergo a standardized sedation protocol managed by an anesthesiologist. Sedation induction will be performed with a loading dose of propofol (0.5-1 mg/kg). Maintenance of sedation will be achieved through a continuous infusion of propofol (40-60 µg/kg/min), supplemented by intermittent bolus doses of 20-30 mg as clinically required. The sedation level will be dynamically titrated by the physician to maintain a target Ramsay Sedation Scale (RSS) score of 3-4 and Bispectral Index (BIS) values between 60 and 80. This approach ensures patient comfort and procedural stability while minimizing respiratory depression

Patients will be randomized 1:1 into two groups:

Group L (Lidocaine): IV bolus 1.0 mg/kg before induction + 2.0 mg/kg/h continuous infusion during the procedure.

Group C (Control): Equal volume of 0.9% Saline. Primary outcome is the "Rescue Spasmolytic Requirement" based on endoscopist's evaluation. Secondary outcomes include duodenal peristalsis score (Suzuki Scale) assessed via video review by a blinded endoscopist, total propofol consumption, and recovery times.

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 85 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients scheduled for elective ERCP.
  • ASA Physical Status I, II, or III.
  • Age between 18 and 85 years.
  • Provided written informed consent.

Exclusion Criteria

  • Allergy to amide-type local anesthetics.
  • Severe hepatic or renal failure.
  • History of AV block or severe cardiac arrhythmia.
  • Pregnancy or lactation.
  • Chronic opioid use.
  • Patient refusal.

Arms & Interventions

Lidocaine Group

Experimental

1.0 mg/kg IV bolus followed by 2.0 mg/kg/h IV infusion during the procedure.

Intervention: Lidocaine Hydrochloride 2% (Drug)

Placebo Group

Placebo Comparator

IV bolus and infusion of 0.9% NaCl matched in volume and rate to the study drug.

Intervention: 0.9 % Normal Saline (Other)

Outcomes

Primary Outcomes

Rescue Spasmolytic Requirement Rate

Time Frame: Intraoperative (During the ERCP procedure, approx. 30 minutes)

The proportion of patients requiring rescue medication (Hyoscine-N-butylbromide or Glucagon) due to severe duodenal spasm preventing cannulation.

Secondary Outcomes

  • Total Propofol Consumption(From induction until the end of the procedure)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Mehmet sahap

Asist Prof Dr

Ankara City Hospital Bilkent

Study Sites (1)

Loading locations...

Similar Trials